- Blackstone-managed funds will pay up to $1.5 billion in development costs through 2028.
Pfizer announced a co-funding agreement with Blackstone Life Sciences for its once-monthly weight-loss drug candidate berobenatide. Blackstone will fund up to $1.5 billion in development costs through 2028, with milestone payments tied to approval and sales. The deal helps Pfizer fund its next growth driver as it faces patent losses on Eliquis and Ibrance.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.